+ 34 986 812 316

Pharmaceutical Chemistry. Sirtuins for Drug Development.
Clinical Research Centre, University of Eastern Finland, Yliopistonranta 1C, 70210 Kuopio

SIRT1, SIRT6, sirtuins, bromodomain, diabetes


Cell culture models (cancer / diabetes).


Cytotoxicity, cell proliferation, cell cycle assays. Recombinant protein production. Protein-protein interactions. Various biochemical and molecular biological methods.

Collaborations outside COST

Short description of ongoing research projects

- Interplay between epigenetic readers and erasers - bromodomain proteins and sirtuins. - Novel inhibitors for sirtuins (SIRT1-3, SIRT6). - The role of sirtuins in type 2 diabetes.

  1. Kokkola T, Suuronen T, Pesonen M, Filippakopoulos P, Salminen A, Jarho EM, Lahtela-Kakkonen M. BET inhibition upregulates SIRT1 and alleviates inflammatory responses. ChemBioChem Jul 2015. doi 10.1002/cbic.201500272.
  2. Seifert T, Malo M, Kokkola T, Engen K, Fridén-Saxin M, Wallén EAA, Lahtela-Kakkonen M, Jarho EM, Luthman K. Chroman-4-one based sirtuin 2 inhibitors with antiproliferative effects. Journal of Medicinal Chemistry 57: 9870-9888, 2014.
  3. Kokkonen P, Rahnasto-Rilla M, Mellini P, Jarho E, Lahtela-Kakkonen M, Kokkola T. Studying SIRT6 regulation using H3K56 based substrate and small molecules. European Journal of Pharmaceutical Sciences 63: 71-76, 2014.
  4. Kokkola T, Suuronen T, Molnár F, Määttä J, Salminen A, Jarho EM, Lahtela-Kakkonen M. AROS has a context-dependent effect on SIRT1. FEBS Letters, 588: 1523-1528, 2014.
  5. Mellini P, Kokkola T, Suuronen T, Salo HS, Tolvanen L, Mai A, Lahtela-Kakkonen M, Jarho EM. Screen of Pseudopeptidic Inhibitors of Human Sirtuins 1-3: Two Lead Compounds with Antiproliferative Effects in Cancer Cells. Journal of Medicinal Chemistry 56: 6681-6695, 2013.
Other activities of potential interest to others

Cost UE